MargaretCallahanMDPhD

Oncology • Farmington, CT

Asst Attending, MSKCC

Join to view full profile

Dr. Callahan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Callahan's full profile

Already have an account?

Office
263 Farmington Ave
Farmington, CT 06030
Phone+1 860-679-2100

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2009 - 2013
University of California (San Francisco)Residency, Internal Medicine, 2007 - 2009
Uconn School Of MedicineClass of 2007

Certifications & Licensure

FL State Medical License 2021 - Present
CT State Medical License 2023 - 2025
NJ State Medical License 2019 - 2025
NH State Medical License 2024 - 2024
NY State Medical License 2008 - 2024
American Board of Internal Medicine Medical Oncology

Clinical Trials

Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection Start of enrollment: 2022 Nov 08
Terminated
Phase 2
Roles: Principal Investigator, Contact
Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) Start of enrollment: 2022 Feb 11
Recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator

Publications & Presentations

PubMed

Decoding Spatial Tissue Architecture: A Scalable Bayesian Topic Model for Multiplexed Imaging Analysis.
Xiyu Peng, James W Smithy, Mohammad Yosofvand, Caroline E Kostrzewa, MaryLena Bleile
Biorxiv. 2024-11-09
Durable complete response in a patient with leptomeningeal melanoma after treatment with dabrafenib, trametinib, and nivolumab.
Sarah E Lochrin, Darren J Buonocore, Robert J Young, Thomas J Kaley, Michael A Postow
Pigment Cell & Melanoma Research. 2024-11-01
1 citations
Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study.
James W Smithy, Hannah L Kalvin, Fiona D Ehrich, Ronak Shah, Matthew Adamow
Clinical Cancer Research. 2024-08-15

Lectures

17th Perspectives In Melanoma
Imedex, Baltimore, Maryland - 9/13/2013
Biologic Therapies V Summit
Cleveland Clinic - Cleveland, Ohio / The Cleveland Clinic Foundation, Cleveland, Ohio - 5/2/2013

Press Mentions

Search News, Events and AnnouncementsJune 6th, 2017
Statins for Cancer: Still UncertainMay 22nd, 2017